DIABETIC KETOACIDOSIS ASSOCIATED WITH EMPAGLIFLOZIN THERAPY : MECHANISMS, RISC FACTORS AND CLINICAL IMPLICATIONS
Najmutdinova D.KTMA Tashkent, UzbekistanKurbanova A.B.TMA Tashkent, Uzbekistan
Zenodo (CERN European Organization for Nuclear Research)repository2026
ABI
Abstract
Empagliflozin, a sodium–glucose co-transporter 2 (SGLT2) inhibitor, is widely prescribed for type 2 diabetes mellitus (T2DM) and heart failure. Despite its proven cardiovascular and renal benefits, rare but serious cases of diabetic ketoacidosis (DKA), including euglycemic DKA (euDKA), have been reported. This article reviews the incidence, mechanisms, risk factors, clinical features, and management strategies of empagliflozin-associated DKA. Early recognition and preventive strategies are essential to balance risks and benefits of therapy.
Identifiers
Citations and references
Cited by 00 references